Zolpidem for Insomnia
Start zolpidem at 5 mg for adults (not 10 mg) and 5 mg for elderly patients, taken immediately before bedtime with at least 7-8 hours available for sleep. The FDA has lowered the recommended starting dose from the original 10 mg to 5 mg due to safety concerns, particularly regarding next-morning impairment 1, 2.
Dosing Recommendations
Immediate-Release Formulations
- Adults: Start at 5 mg at bedtime; may increase to 10 mg if clinically needed
- Elderly or debilitated patients: 5 mg maximum (do not exceed)
- Women: Particularly important to start at 5 mg due to slower drug clearance and higher risk of next-morning impairment
Extended-Release Formulations
- Adults: 6.25 mg at bedtime (FDA-reduced from original 12.5 mg)
- Elderly: 6.25 mg maximum
- Use for: Sleep maintenance insomnia (difficulty staying asleep) 1
Sublingual Formulations
- Middle-of-night awakening: 1.75 mg (women) or 3.5 mg (men) when ≥4 hours of sleep time remain
- Sleep onset: 5 mg (women) or 10 mg (men) sublingual at bedtime 3, 4
Clinical Efficacy
Zolpidem demonstrates clinically significant improvements in:
- Sleep onset latency: Reduces time to fall asleep by approximately 15 minutes compared to placebo 1, 5, 2
- Total sleep time: Increases by 23-48 minutes depending on formulation and dosing schedule 1, 5
- Sleep maintenance: Extended-release formulations show moderate reduction in wake after sleep onset 1
- Sleep quality: Moderately large improvements based on subjective measures 1
The evidence quality is rated as very low to low due to heterogeneity, imprecision, and publication bias, resulting in a WEAK recommendation from the American Academy of Sleep Medicine 1.
Duration of Treatment
Long-term use up to 6-12 months is supported by evidence without significant tolerance or rebound insomnia at recommended doses 2, 6. The 24-week study of extended-release zolpidem 12.5 mg (3-7 nights/week) demonstrated sustained efficacy with 89.8% of patients reporting favorable sleep aid at 12 weeks and 92.3% at 24 weeks 6. No objective rebound insomnia was observed upon discontinuation at recommended doses 2.
Critical Safety Considerations
Timing and Administration
- Take immediately before bedtime with at least 7-8 hours available for sleep
- Never take after a meal or with alcohol
- Do not take if middle-of-night awakening occurs unless using sublingual low-dose formulation specifically indicated for this purpose
High-Risk Populations Requiring Dose Reduction or Avoidance
- Women: Higher plasma concentrations and slower clearance necessitate lower starting doses
- Elderly patients: Increased sensitivity and fall risk; maximum 5 mg immediate-release or 6.25 mg extended-release
- Hepatic impairment: Reduced clearance requires dose reduction
- Psychiatric comorbidities: Higher risk of complex sleep behaviors and hallucinations 7
Serious Adverse Effects
Complex sleep-related behaviors occur and can be dangerous:
- Sleep-driving, sleep-eating, sleep-walking
- Often unrecognized by patient
- Can result in serious injury or legal consequences 7
- Discontinue immediately if these occur
Neuropsychiatric effects include:
- Amnesia (particularly anterograde amnesia within 90 minutes of dosing) 2
- Hallucinations and perceptual disturbances 7
- Dizziness and somnolence 1
Next-morning impairment:
- Driving and cognitive performance may be impaired 8+ hours after dosing, especially with 10 mg doses
- Women and elderly at highest risk
- Warn patients not to drive or operate machinery if feeling drowsy 2
Common Adverse Effects
- Headache, dizziness, somnolence (small but statistically significant increases vs. placebo) 1
- Withdrawal due to adverse effects: 6% vs. 3% with placebo 5
Fracture and Mortality Risk
Observational data show increased fracture risk (adjusted OR 1.72) in zolpidem users 5. Mortality data are inconsistent and require further investigation.
Clinical Decision Algorithm
Step 1: Confirm chronic insomnia diagnosis (difficulty initiating/maintaining sleep ≥3 months)
Step 2: Determine insomnia subtype:
- Sleep onset only → Immediate-release zolpidem 5 mg OR zaleplon 10 mg
- Sleep maintenance → Extended-release zolpidem 6.25 mg OR doxepin 3-6 mg
- Both onset and maintenance → Extended-release zolpidem 6.25 mg
- Middle-of-night awakening → Sublingual zolpidem low-dose (if ≥4 hours sleep time remains)
Step 3: Screen for contraindications:
- Severe hepatic impairment
- History of complex sleep behaviors
- Concurrent CNS depressants or alcohol use
- Pregnancy (limited safety data; consider alternatives) 8
Step 4: Initiate at lowest effective dose:
- Start 5 mg immediate-release or 6.25 mg extended-release
- Reassess after 1-2 weeks
- Increase to 10 mg immediate-release or 12.5 mg extended-release only if inadequate response and no adverse effects
Step 5: Monitor for:
- Next-morning impairment (especially first few doses)
- Complex sleep behaviors
- Efficacy on sleep parameters
- Emergence of tolerance (rare at recommended doses)
Step 6: Duration strategy:
- Can use nightly for up to 6-12 months based on evidence 6
- Consider intermittent dosing (3-5 nights/week) to minimize exposure while maintaining efficacy 1
- Combine with cognitive behavioral therapy for insomnia (CBT-I) when possible
Important Caveats
The 10 mg dose studied in most trials is no longer the recommended starting dose due to FDA safety concerns identified post-marketing 1. While efficacy data are strongest for 10 mg, the risk-benefit ratio favors starting at 5 mg.
Zolpidem carries a WEAK recommendation from the AASM, meaning clinical judgment and patient preferences should heavily influence the decision 1. Consider alternatives like dual orexin receptor antagonists (DORAs) which have more favorable safety profiles regarding complex sleep behaviors and no evidence of withdrawal or abuse potential 9.
Do not use zolpidem as first-line monotherapy—it should be part of a comprehensive approach that includes sleep hygiene education and consideration of CBT-I, which has more durable long-term benefits.